title: Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma.
abstract: The matrix protein osteopontin has been shown to be a marker of osteoclastic activity in multiple myeloma patients, as well as a regulator of angiogenesis. We measured serum levels of osteopontin in 50 untreated multiple myeloma patients (in 25, also after treatment) and examined the relation to markers of osteolytic and angiogenic activity. The median (range) of serum osteopontin was 85 (5-232) in the patient group vs. 36 (2-190) ng/ml in the control group. Serum osteopontin levels were significantly higher in patients with advanced stage or grade of myeloma disease. All patients with serum osteopontin levels >100 ng/ml had advanced stage (II or III) or high grade bone disease, whereas stage I or low grade patients had serum osteopontin levels <100ng/ml. Serum osteopontin levels significantly decreased after treatment. There was a positive correlation of osteopontin with the bone turnover marker N-terminal propeptide of procollagen type I (NTx) and the angiogenic markers vascular endothelial growth factor (VEGF) and bone marrow microvessel density (r: 0.35, 0.47 and 0.30 respectively, p < 0.05). These results support osteopontin as a dual marker of bone destruction and angiogenic activity in myeloma patients. Osteopontin represents a useful biomarker for monitoring myeloma disease activity.
authors.affiliation: Department of Hematology, University Hospital of Heraklion, Crete, Greece.
authors.forename: Aikaterini
authors.initials: A
authors.lastname: Sfiridaki
authors.forename: Spiros
authors.initials: S
authors.lastname: Miyakis
authors.forename: Constantina
authors.initials: C
authors.lastname: Pappa
authors.forename: George
authors.initials: G
authors.lastname: Tsirakis
authors.forename: Athanasios
authors.initials: A
authors.lastname: Alegakis
authors.forename: Vasileios
authors.initials: V
authors.lastname: Kotsis
authors.forename: Efstathios
authors.initials: E
authors.lastname: Stathopoulos
authors.forename: Michael
authors.initials: M
authors.lastname: Alexandrakis
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood*; D001862:Bone Resorption / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000098:blood supply; D009389:Neovascularization, Pathologic / Q000097:blood; D053495:Osteopontin / Q000097:blood*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D015415:Biomarkers; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D053495:Osteopontin